Lexaria Bioscience Corp. LXRP Archives - Page 17 of 27

FridayAug 17, 2018 1:41 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Progress in Revolutionary Alternative to Smoking for Drug Delivery

Smoking-related deaths have reached six million a year worldwide Lexaria’s patented drug delivery platform aims to deliver commonly smoked drugs in a non-smoking form factor that sidesteps smoking’s hazards Second round of testing continues to indicate that patented DehydraTECH™ platform provides rapid delivery with high bioavailability As world drug industry regulations undergo revolutionary change and increasingly healthy populations find themselves challenged to meet the cares of old age, Canadian biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is forging a path that establishes it as a pioneer in the field of drug delivery platforms. Lexaria’s mission is to ensure…

WednesdayAug 15, 2018 2:29 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Continues to Demonstrate Versatility

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is the developer of a disruptive drug delivery platform, DehydraTECH™, that the company out-licenses to entities aiming to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. An article discussing the company’s technology reads: “Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has already received some eight patents granted and nearly 50 pending worldwide, and the company has applied for one more to the USPTO. This is because, in lab studies, the proprietary technology has shown evidence of transporting active pharmaceutical ingredients (APIs) across…

MondayAug 13, 2018 11:32 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human Clinical Study on TurboCBD Capsules Corroborates Earlier DehydraTECH Test Results

Significant bioavailability results were reported from LXRP’s randomized, double-blind European study that evaluated its proprietary TurboCBD capsules, powered by DehydraTECH Results corroborate and confirm in vitro and in vivo studies of DehydraTECH technology that measured high levels of drug delivery being achieved faster than with matching controls LXRP says that it is pleased that DehydraTECH has, to date, repeatedly proved evidence of success within human studies; technology earlier demonstrated ability to deliver nicotine Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is pleased to report significant bioavailability results from its randomized and double-blind European human clinical study of DehydraTECH™ powered TurboCBD™…

TuesdayAug 07, 2018 10:21 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Successful Delivery of Nicotine Within Minutes in Edible Nicotine Study

Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced that within minutes after dosing in an animal in vivo study, it has successfully delivered nicotine in an edible form into blood plasma. Per the update, Lexaria's DehydraTECH™ technology delivered nicotine with 90.2% greater delivery than the concentration-matched control formulation by the 10-minute mark and substantially greater absorption levels than the control formulation at all time intervals in the study. The company contracted a third-party laboratory to conduct the study which concentrated on detailed analysis of absorption over a 60-minute period. Lexaria's in vitro laboratory, in vivo…

FridayAug 03, 2018 1:55 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enabling Companies to Produce High-Quality Cannabis-Infused Products

80 percent of the company’s total revenue anticipated from the licensing of DehydraTECH™ Nuke Enterprises renewed its license, sending a strong vote of confidence in the technology Enabled GP Holdings to create a high-performing cannabis-infused beverage Biolog Inc. is developing products which will allow processors and consumers to turn almost any food or beverage into a cannabis edible Beginning production of a line of cannabis-infused alcohol-free beverages through a new licensing agreement Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, utilizes its unique patented DehydraTECH™ delivery technology to enhance the products of its clients. This patented…

WednesdayAug 01, 2018 9:30 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Encouraging Bioavailability Results from TurboCBD™ Study

Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning reported noteworthy bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™. TurboCBD™ is a proprietary, DehydraTECH™ powered, cannabidiol ("CBD") fortified hemp oil capsule developed by Lexaria. The study evaluated the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers. The study compared the 90 mg dose of Lexaria's TurboCBD™ to a 90 mg dose of a positive control formulation without Lexaria's DehydraTECH™ technology. Per the report, Lexaria's TurboCBD™ capsules continued to…

TuesdayJul 31, 2018 9:55 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Definitive Agreement with Hill Street Beverage Company, Inc. (TSXV: BEER)

Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), together with Hill Street Beverage Company (TSXV: BEER), this morning announced that the companies have signed a definitive agreement to license Lexaria's DehydraTECH™ for five years on a semi-exclusive basis to produce a line of cannabis-infused alcohol-free beverages to be distributed in Canada following regulatory approval. The purchase price shall be partially paid to Lexaria in common shares in the capital of Hill Street totaling $56,250, which is equal to 419,982 common shares. The issuance of the shares is subject to regulatory approval. "Hill Street's award-winning and great-tasting wines and…

ThursdayJul 26, 2018 12:39 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH May Play Larger Role in Treating Nervous System Disorders and Diseases

LXRP files for patent with the USPTO for DehydraTECH’s innovative treatment options for diseases and disorders including Alzheimer’s, Huntington’s and Parkinson’s Company hopes to leverage this future possible patent to commercialize its development or out-licensing of future new products that treat central nervous system diseases DehydraTECH platform, being lab tested for drug delivery, effectively transported nicotine across the blood brain barrier, a barrier that protects the brain and makes traditional treatment difficult Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has already received some eight patents granted and nearly 50 pending worldwide, and the company has…

TuesdayJul 24, 2018 1:57 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Applicable to Multiple Industries

Active investigation phase in the EU, Canada, China, Japan and India Forming four new wholly owned subsidiaries Seeks to acquire an equitable tax treatment Cannabinoids are poorly absorbed by the body’s gastrointestinal tract, a trait that Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) lipophilic enhancement technology DehydraTECH™ is changing. Previously, consumers have turned to cannabis smoking to achieve higher effectiveness. However, human clinical studies have shown DehydraTECH™ to have a quick rate of absorption, allowing users to avoid the risks associated with smoking. DehydraTECH™ offers improved taste and smell, with effects felt within 15 to 20 minutes as opposed to…

MondayJul 23, 2018 11:18 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Proceeding with Reorgani-zation into Four Subsidiaries

LXRP’s patented DehydraTECH technology will be employed by each wholly owned subsidiary, with applications applied to the industry segments At its 2018 Annual General and Special Meeting (AGM), all motions were passed, including election of board members and approval of its conversion plan Move to convert the company from a U.S.-based firm to Canada-based is placed on ‘indefinite hold’ due to inequitable tax treatment issue; LXRP to seek a resolution At Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) 2018 Annual General Meeting, all motions were passed. The company is proceeding on schedule with its reorganization into four new wholly owned…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP